Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety trial of pitavastatin PLGA nanoparticles in retinitis pigmentosa
jRCT2071260006Phase 1Recruiting
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pitavastatin in retinitis pigmentosa (RP), sponsored by none. Primary endpoint: Incidence of adverse events. Started Jun 2026; status: recruiting.
02
Drugs
pitavastatin
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on jRCT2071260006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260006.